Literature DB >> 35978151

SMARCE1 promotes neuroblastoma tumorigenesis through assisting MYCN-mediated transcriptional activation.

Xiaosong Hu1,2, Ruochen Liu1,2, Jianbing Hou1,2, Wen Peng1,2, Sicheng Wan1,2, Minghao Xu1,2, Yongsen Li1,2, Guanghui Zhang1,2, Xuan Zhai3,4, Ping Liang5,6, Hongjuan Cui7,8.   

Abstract

SMARCE1 gene, encoding a core subunit of SWI/SNF chromatin remodeling complex, is situated on chromosome 17q21-ter region that is frequently gained in neuroblastoma. However, its role in the tumorigenesis remains unknown. Here, we showed that high expression of SMARCE1 was associated with poor prognosis of patients with neuroblastoma, especially those with MYCN amplification. Knockdown of SMARCE1 reduced proliferation, colony formation, and tumorigenicity of neuroblastoma cells. Mechanistically, SMARCE1 directly interacted with MYCN, which was necessary for MYCN-mediated transcriptional activation of downstream target genes including PLK1, ODC1, and E2F2. Overexpression of PLK1, ODC1 or E2F2 significantly reversed the inhibiting effect of SMARCE1 knockdown on the proliferation, colony formation, and tumorigenicity of MYCN-amplified neuroblastoma cells. Moreover, we revealed that MYCN directly regulated SMARCE1 transcription through binding to a non-canonical E-box of SMARCE1 promoter, thus enhancing SMARCE1-MYCN cooperativity. These findings establish SMARCE1 is a critical oncogenic factor in neuroblastoma and provide a new potential target for treatment of neuroblastoma with 17q21-ter gain and MYCN amplification.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35978151     DOI: 10.1038/s41388-022-02428-1

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   8.756


  65 in total

1.  MYCN amplification and 17q in neuroblastoma: evidence for structural association.

Authors:  S O'Neill; L Ekstrom; M Lastowska; P Roberts; G M Brodeur; U R Kees; M Schwab; N Bown
Journal:  Genes Chromosomes Cancer       Date:  2001-01       Impact factor: 5.006

2.  IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma.

Authors:  Jessica L Bell; Raseswari Turlapati; Tao Liu; Johannes H Schulte; Stefan Hüttelmaier
Journal:  J Clin Oncol       Date:  2015-03-09       Impact factor: 44.544

Review 3.  Neuroblastoma.

Authors:  Katherine K Matthay; John M Maris; Gudrun Schleiermacher; Akira Nakagawara; Crystal L Mackall; Lisa Diller; William A Weiss
Journal:  Nat Rev Dis Primers       Date:  2016-11-10       Impact factor: 52.329

4.  Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma.

Authors:  N Bown; S Cotterill; M Lastowska; S O'Neill; A D Pearson; D Plantaz; M Meddeb; G Danglot; C Brinkschmidt; H Christiansen; G Laureys; F Speleman; J Nicholson; A Bernheim; D R Betts; J Vandesompele; N Van Roy
Journal:  N Engl J Med       Date:  1999-06-24       Impact factor: 91.245

5.  Cloning, chromosomal location, and expression analysis of murine Smarce1-related, a new member of the high-mobility 365 group gene family.

Authors:  F Wattler; S Wattler; M Kelly; H B Skinner; M Nehls
Journal:  Genomics       Date:  1999-09-01       Impact factor: 5.736

6.  High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma.

Authors:  A Islam; H Kageyama; N Takada; T Kawamoto; H Takayasu; E Isogai; M Ohira; K Hashizume; H Kobayashi; Y Kaneko; A Nakagawara
Journal:  Oncogene       Date:  2000-02-03       Impact factor: 9.867

7.  Crystal structure of the HMG domain of human BAF57 and its interaction with four-way junction DNA.

Authors:  Yunseok Heo; Jae-Hyun Park; Jongmin Kim; Jeongmin Han; Ji-Hye Yun; Weontae Lee
Journal:  Biochem Biophys Res Commun       Date:  2020-09-30       Impact factor: 3.575

8.  JMJD6 is a tumorigenic factor and therapeutic target in neuroblastoma.

Authors:  Matthew Wong; Yuting Sun; Zhichao Xi; Giorgio Milazzo; Rebecca C Poulos; Christoph Bartenhagen; Jessica L Bell; Chelsea Mayoh; Nicholas Ho; Andrew E Tee; Xiaoqiong Chen; Yang Li; Roberto Ciaccio; Pei Y Liu; Chen C Jiang; Qing Lan; Nisitha Jayatilleke; Belamy B Cheung; Michelle Haber; Murray D Norris; Xu D Zhang; Glenn M Marshall; Jenny Y Wang; Stefan Hüttelmaier; Matthias Fischer; Jason W H Wong; Hongxi Xu; Giovanni Perini; Qihan Dong; Rani E George; Tao Liu
Journal:  Nat Commun       Date:  2019-07-25       Impact factor: 17.694

Review 9.  Neuroblastoma and the epigenome.

Authors:  Irfete S Fetahu; Sabine Taschner-Mandl
Journal:  Cancer Metastasis Rev       Date:  2021-01-06       Impact factor: 9.264

10.  An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability.

Authors:  Zsuzsanna Nagy; Janith A Seneviratne; Maxwell Kanikevich; William Chang; Chelsea Mayoh; Pooja Venkat; Yanhua Du; Cizhong Jiang; Alice Salib; Jessica Koach; Daniel R Carter; Rituparna Mittra; Tao Liu; Michael W Parker; Belamy B Cheung; Glenn M Marshall
Journal:  Nat Commun       Date:  2021-03-25       Impact factor: 14.919

View more
  1 in total

Review 1.  Polycomb Directed Cell Fate Decisions in Development and Cancer.

Authors:  Beatriz German; Leigh Ellis
Journal:  Epigenomes       Date:  2022-09-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.